Evidence map›Paper›PMID 32383062›Full record

ArticleInflammopharmacology2020

APPA (apocynin and paeonol) modulates pathological aspects of human neutrophil function, without supressing antimicrobial ability, and inhibits TNFα expression and signalling.

A L Cross, J Hawkes, H L Wright, R J Moots, S W Edwards

Open access · hybridAbstract read
In one paragraph

Article in Inflammopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Frontiers in pharmacology · 2024
    Article
  11. Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

A L CrossInstitute of Ageing and Chronic Disease, Aintree University Hospital, Longmoor Lane, Liverpool, L9 7AL, UK.
J HawkesInstitute of Ageing and Chronic Disease, Aintree University Hospital, Longmoor Lane, Liverpool, L9 7AL, UK.
H L WrightInstitute of Ageing and Chronic Disease, Aintree University Hospital, Longmoor Lane, Liverpool, L9 7AL, UK.
R J MootsInstitute of Ageing and Chronic Disease, Aintree University Hospital, Longmoor Lane, Liverpool, L9 7AL, UK.
S W EdwardsInstitute of Integrative Biology, University of Liverpool, Liverpool, L69 7ZB, UK. s.w.edwards@liv.ac.uk.ORCID http://orcid.org/0000-0002-7074-0552
University of Liverpool · GB

Funding

Versus Arthritis 21430
6 · The paper itself

Abstract

Neutrophils are key players in the pathophysiological process underlying inflammatory conditions not only by release of tissue-damaging cytotoxic enzymes, reactive oxygen species (ROS) but also by secretion of important immunomodulatory chemokines and cytokines. Here, we report the effects of the novel agent APPA, undergoing formal clinical development for treatment of osteoarthritis, and its constituent components, apocynin (AP) and paeonol (PA) on a number of neutrophil functions, including effects on TNFα- expression and signalling. Neutrophils were treated with APPA (10-1000 µg/mL) prior to the measurement of cell functions, including ROS production, chemotaxis, apoptosis and surface receptor expression. Expression levels of several key genes and proteins were measured after incubation with APPA and the chromatin re-modelling agent, R848. APPA did not significantly affect phagocytosis, bacterial killing or expression of surface receptors, while chemotactic migration was affected only at the highest concentrations. However, APPA down-regulated neutrophil degranulation and ROS levels, and decreased the formation of neutrophil extracellular traps. APPA also decreased cytokine-stimulated gene expression, inhibiting both TNFα- and GM-CSF-induced cell signalling. APPA was as effective as infliximab in down-regulating chemokine and IL-6 expression following incubation with R848. Whilst APPA does not interfere with neutrophil host defence against infections, it does inhibit neutrophil degranulation, and cytokine-driven signalling pathways (e.g. autocrine signalling and NF-κB activation), processes that are associated with inflammation. These observations may explain the mechanisms by which APPA exerts anti-inflammatory effects and suggests a potential therapeutic role in inflammatory diseases in which neutrophils and TNFα signalling are important in pathology, such as rheumatoid arthritis.

Indexed as

AcetophenonesAnti-Inflammatory AgentsApoptosisCells, CulturedCytokinesDose-Response Relationship, DrugDrug CombinationsHumansInflammationNeutrophilsReactive Oxygen SpeciesSignal TransductionTumor Necrosis Factor-alphaAcetophenonesacetovanilloneAnti-Inflammatory AgentsCytokinesDrug CombinationspaeonolReactive Oxygen SpeciesTNF protein, humanTumor Necrosis Factor-alphaApocyninAPPANeutrophilNFκBPaeonolRheumatoid arthritis

Identifiers

PMID32383062
PMCPMC7525285
OpenAlexW3021314277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.